Search results
The FDA Now Wants Fall COVID Vaccines to Target KP.2—But Not All Manufacturers Can Pivot
Verywell Health via Yahoo News· 4 days agoLess than a week after telling COVID-19 vaccine manufacturers to target the JN.1 variant this fall,...
A Synergy Of Excellence: Novavax-Mabion Partnership During Unprecedented Times Amid The Covid-19...
BioresearchOnline· 5 days agoNovavax's COVID-19 vaccine, Nuvaxovid, was developed in record time with the support of Mabion, a...
FDA advises vaccine manufacturers to make COVID-19 booster targeting KP.2 strain
ABC Action News Tampa Bay· 8 hours agoThe FDA has issued an updated recommendation for the fall COVID-19 vaccine formula. "Coverage in the...
Novavax’s South African Phase IIb COVID-19 vaccine trial likely to reveal results within next...
Pharmaceutical Technology via Yahoo Finance· 6 days agoSouth Africa’s existing regulatory, consent and ethics frameworks around HIV vaccine trial investigations helped with regards to quick initiation and straightforward progress of COVID-19 vaccine trials in the country, the source said.
3 Short-Squeeze Stocks Ready to Break the Chains of Bearish Sentiment
InvestorPlace via Yahoo Finance· 6 days agoIt was not long ago that Novavax (NASDAQ:NVAX) was among the stocks with high short interest. The...
3 Short-Squeeze Stocks Ready to Break the Chains of Bearish Sentiment
InvestorPlace· 6 days agoIt was not long ago that Novavax (NASDAQ:NVAX) was among the stocks with high short interest. In the...
Novavax applies for FDA nod for its updated COVID vaccine
Center for Infectious Disease Research and Policy· 7 days agoThe company said it will have the vaccine ready to distribute in mid July as prefilled syringes, pending approval and recommendations.
We Won't Solve Long COVID Until We Decide What It Is
Medscape· 7 days agoIs a slow recovery from COVID-19 the lingering effects of a bad infection or the start of a new syndrome?
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 4 days agoThough it has a booster Covid shot, like rivals Moderna and Novavax, analysts don't expect sales to...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 4 days agoThe company noted that it achieved 48% market share for Covid vaccines in the U.S. during the fall...